TFM
CRSP icon

TFC Financial Management’s CRISPR Therapeutics CRSP Stock Holding History

TFC Financial Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.7K Hold
688
– – ﹤0.01% 309
2025
Q4 		$36.1K Hold
688
– – ﹤0.01% 298
2025
Q3 		$44.6K Sell
688
-30
-4% -$1.72K 0.01% 278
2025
Q2 		$34.9K Hold
718
– – ﹤0.01% 291
2025
Q1 		$24.4K Buy
718
+40
+6% +$1.7K ﹤0.01% 307
2024
Q4 		$26.7K Sell
678
-80
-11% -$3.78K ﹤0.01% 291
2024
Q3 		$35.6K Buy
758
+58
+8% +$2.94K 0.01% 281
2024
Q2 		$37.8K Hold
700
– – 0.01% 255
2024
Q1 		$47.7K Hold
700
– – 0.01% 236
2023
Q4 		$43.8K Buy
700
+680
+3,400% +$37.6K 0.01% 237
2023
Q3 		$908 Hold
20
– – ﹤0.01% 537
2023
Q2 		$1.12K Hold
20
– – ﹤0.01% 503
2023
Q1 		$905 Hold
20
– – ﹤0.01% 517
2022
Q4 		$813 Hold
20
– – ﹤0.01% 480
2022
Q3 		$1K Hold
20
– – ﹤0.01% 456
2022
Q2 		$1K Hold
20
– – ﹤0.01% 448
2022
Q1 		$1K Sell
20
-269
-93% -$16.9K ﹤0.01% 468
2021
Q4 		$22K Hold
289
– – 0.01% 267
2021
Q3 		$32K Hold
289
– – 0.01% 232
2021
Q2 		$47K Hold
289
– – 0.02% 207
2021
Q1 		$35K Hold
289
– – 0.01% 213
2020
Q4 		$44K Buy
289
+20
+7% +$2.36K 0.02% 199
2020
Q3 		$22K Buy
+269
New +$23.9K 0.01% 229

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TFC Financial Management's CRSP Position: Q1 2026 in Review

TFC Financial Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 688 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #309.

TFC Financial Management first reported a position in CRSP in Q3 2020 and has held it in 23 quarters since. The position peaked at $47.7K in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • TFC Financial Management held 688 shares of CRISPR Therapeutics worth $32.7K as of Q1 2026.
  • TFC Financial Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of TFC Financial Management's portfolio in Q1 2026, its #309 holding.
  • TFC Financial Management first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • TFC Financial Management's CRISPR Therapeutics position peaked at $47.7K in Q1 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on TFC Financial Management's 13F filing for Q1 2026, filed 23 Apr 2026.